Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

2008 • 7,243 citations

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1984 • 6,841 citations

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

2008 • 5,528 citations

Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

2006 • 4,668 citations

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 • 4,320 citations

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

2008 • 3,870 citations

EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 • 3,807 citations

PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo

1995 • 3,456 citations

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

2005 • 3,450 citations

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

2006 • 3,099 citations

Epidermal growth factor receptor mutations in lung cancer

2007 • 2,966 citations

mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

2002 • 2,904 citations

The Genomic Landscapes of Human Breast and Colorectal Cancers

2007 • 2,716 citations

Somatic mutations affect key pathways in lung adenocarcinoma

2008 • 2,653 citations

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

2006 • 2,463 citations

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

2002 • 2,056 citations

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

2002 • 1,831 citations

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

2004 • 1,785 citations

Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action

2002 • 1,758 citations

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

2007 • 1,571 citations

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

2008 • 1,332 citations

BRAF mutation predicts sensitivity to MEK inhibition

2005 • 1,312 citations

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

2008 • 1,306 citations

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

2008 • 722 citations

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

2006 • 587 citations

^V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

2009 • 578 citations

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

2005 • 490 citations

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

2009 • 481 citations

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

2009 • 445 citations

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

2008 • 382 citations

TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin

1995 • 298 citations

Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions

2009 • 265 citations

A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes

2006 • 233 citations

Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

2008 • 227 citations

Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

2007 • 174 citations

HER2 ^YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

2009 • 171 citations

Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors

2007 • 123 citations

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

2009 • 112 citations

Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α

2008 • 96 citations